(JAZZ) Jazz Pharmaceuticals - Ratings and Ratios
Xywav, Xyrem, Epidiolex, Rylaze, Vyxeos
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 31.6% |
| Value at Risk 5%th | 47.8% |
| Relative Tail Risk | -8.13% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.95 |
| Alpha | 28.33 |
| CAGR/Max DD | 0.12 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.527 |
| Beta | 0.733 |
| Beta Downside | 1.106 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.07% |
| Mean DD | 21.82% |
| Median DD | 22.94% |
Description: JAZZ Jazz Pharmaceuticals November 06, 2025
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a Dublin-based specialty biopharma that develops and commercializes products across neurology, oncology, and hematology in the U.S., Europe, and other markets. Its approved portfolio includes Xywav and Xyrem for narcolepsy-related sleep disorders, Epidiolex for rare epilepsies, Rylaze/Enrylaze for acute lymphoblastic leukemia/lymphoblastic lymphoma, Zepzelca for small-cell lung cancer, Ziihera for HER-2 positive biliary tract cancers, Defitelio for veno-occlusive disease, and Vyxeos for therapy-related acute myeloid leukemia. The pipeline features late-stage assets such as Zanidatamab (Phase 3 HER-2 GEA), Suvecaltamide (Phase 2 Parkinson’s tremor), and several early-stage candidates targeting RAF kinase, interferon-alpha, and sleep disorders.
Key quantitative points (FY 2023): revenue of approximately $2.5 billion, with >55 % derived from specialty CNS and oncology products; R&D intensity around 15 % of sales, reflecting a focus on high-margin, niche indications; and a cash-and-equivalents position of roughly $1.2 billion, providing runway for upcoming trial readouts. Macro-level drivers include an aging population that expands demand for sleep-disorder therapies, continued growth in the global oncology market (projected CAGR ≈ 6 % through 2030), and favorable reimbursement trends for specialty drugs in the U.S.
For a deeper quantitative assessment, the ValueRay platform provides a granular breakdown of Jazz’s valuation metrics and scenario analysis.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (-368.5m TTM) > 0 and > 6% of Revenue (6% = 249.5m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 2.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 35.64% (prev 84.16%; Δ -48.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 1.39b > Net Income -368.5m (YES >=105%, WARN >=100%) |
| Net Debt (4.19b) to EBITDA (257.5m) ratio: 16.28 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (61.6m) change vs 12m ago -2.48% (target <= -2.0% for YES) |
| Gross Margin 85.39% (prev 85.58%; Δ -0.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 35.22% (prev 32.58%; Δ 2.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.13 (EBITDA TTM 257.5m / Interest Expense TTM 200.9m) >= 6 (WARN >= 3) |
Altman Z'' 0.72
| (A) 0.13 = (Total Current Assets 3.76b - Total Current Liabilities 2.27b) / Total Assets 11.36b |
| (B) 0.04 = Retained Earnings (Balance) 442.7m / Total Assets 11.36b |
| (C) -0.04 = EBIT TTM -428.0m / Avg Total Assets 11.81b |
| (D) -0.02 = Book Value of Equity -126.6m / Total Liabilities 7.40b |
| Total Rating: 0.72 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 51.08
| 1. Piotroski 5.0pt |
| 2. FCF Yield 9.46% |
| 3. FCF Margin 32.14% |
| 4. Debt/Equity 1.37 |
| 5. Debt/Ebitda 16.28 |
| 6. ROIC - WACC (= -11.87)% |
| 7. RoE -9.25% |
| 8. Rev. Trend 70.83% |
| 9. EPS Trend -30.97% |
What is the price of JAZZ shares?
Over the past week, the price has changed by -4.85%, over one month by +24.38%, over three months by +32.75% and over the past year by +41.57%.
Is JAZZ a buy, sell or hold?
- Strong Buy: 10
- Buy: 6
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the JAZZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 208.5 | 21.1% |
| Analysts Target Price | 208.5 | 21.1% |
| ValueRay Target Price | 188.5 | 9.5% |
JAZZ Fundamental Data Overview November 29, 2025
P/E Forward = 8.7336
P/S = 2.5856
P/B = 2.7155
P/EG = 4.1604
Beta = 0.332
Revenue TTM = 4.16b USD
EBIT TTM = -428.0m USD
EBITDA TTM = 257.5m USD
Long Term Debt = 4.33b USD (from longTermDebt, last quarter)
Short Term Debt = 1.04b USD (from shortTermDebt, last quarter)
Debt = 5.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.19b USD (from netDebt column, last quarter)
Enterprise Value = 14.13b USD (10.75b + Debt 5.43b - CCE 2.05b)
Interest Coverage Ratio = -2.13 (Ebit TTM -428.0m / Interest Expense TTM 200.9m)
FCF Yield = 9.46% (FCF TTM 1.34b / Enterprise Value 14.13b)
FCF Margin = 32.14% (FCF TTM 1.34b / Revenue TTM 4.16b)
Net Margin = -8.86% (Net Income TTM -368.5m / Revenue TTM 4.16b)
Gross Margin = 85.39% ((Revenue TTM 4.16b - Cost of Revenue TTM 607.4m) / Revenue TTM)
Gross Margin QoQ = 77.11% (prev 88.88%)
Tobins Q-Ratio = 1.24 (Enterprise Value 14.13b / Total Assets 11.36b)
Interest Expense / Debt = 0.89% (Interest Expense 48.6m / Debt 5.43b)
Taxrate = -2683 % (out of range, set to none) (-242.4m / 9.04m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.65 (Total Current Assets 3.76b / Total Current Liabilities 2.27b)
Debt / Equity = 1.37 (Debt 5.43b / totalStockholderEquity, last quarter 3.96b)
Debt / EBITDA = 16.28 (Net Debt 4.19b / EBITDA 257.5m)
Debt / FCF = 3.14 (Net Debt 4.19b / FCF TTM 1.34b)
Total Stockholder Equity = 3.98b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.24% (Net Income -368.5m / Total Assets 11.36b)
RoE = -9.25% (Net Income TTM -368.5m / Total Stockholder Equity 3.98b)
RoCE = -5.15% (EBIT -428.0m / Capital Employed (Equity 3.98b + L.T.Debt 4.33b))
RoIC = -6.08% (negative operating profit) (EBIT -428.0m / (Assets 11.36b - Curr.Liab 2.27b - Cash 2.05b))
WACC = 5.79% (E(10.75b)/V(16.18b) * Re(8.71%) + (debt cost/tax rate unavailable))
Discount Rate = 8.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -5.97%
[DCF Debug] Terminal Value 78.70% ; FCFE base≈1.25b ; Y1≈1.49b ; Y5≈2.31b
Fair Price DCF = 573.6 (DCF Value 34.86b / Shares Outstanding 60.8m; 5y FCF grow 19.69% → 3.0% )
EPS Correlation: -30.97 | EPS CAGR: 19.18% | SUE: 0.91 | # QB: 1
Revenue Correlation: 70.83 | Revenue CAGR: 6.26% | SUE: 0.49 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.44 | Chg30d=+0.084 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=22.71 | Chg30d=+1.385 | Revisions Net=+6 | Growth EPS=+180.0% | Growth Revenue=+6.8%
Additional Sources for JAZZ Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle